Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Camibirstat · FHD-286

Small molecule · Inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2) · developed by Foghorn Therapeutics

Phase 2 Most advanced trial
FHTX Developer
1 Registered trials

What is Camibirstat?

Camibirstat (FHD-286) is an orally bioavailable, allosteric small molecule that binds and inhibits BRG1 (SMARCA4) and BRM (SMARCA2), the mutually exclusive ATPase subunits of BAF (SWI/SNF) chromatin remodeling complexes. It is being studied in small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FHD-286
Drug type
Small molecule
Targets
BRG1 (SMARCA4), BRM (SMARCA2)
Mechanism
Inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2)
Pathways
SWI/SNF (BAF) chromatin remodeling, gene expression regulation, oncogenic pathway downregulation
Therapy area
Oncology
Developer
Foghorn Therapeutics Inc. (FHTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
QHA5XLA4SA

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07551635 Phase 2 Small Cell Lung Cancer Not yet recruiting FHTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Small Cell Lung Cancer

More from Foghorn Therapeutics

FHD-609 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the FHTX page.

Follow FHTX, the company behind Camibirstat

See FHTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FHTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.